BTZ is a proteasome inhibitor that is the first-line treatment for multiple myeloma and mantle cell lymphoma, and BTZ-induced peripheral neuropathy (BIPN) is estimated to occur in 37-44% of patients (Grisold et al., 2012). The gene discussed is CASC3; the disease is peripheral neuropathy.